Trial Profile
Evaluation of Satisfaction in Patients Receiving PegIntron Pen [peginterferon alfa-2b]/Rebetol [ribavirin] for Hepatitis C
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SATISFACTION
- Sponsors Merck Sharp & Dohme Corp.
- 07 Aug 2009 Actual patient number changed from (1960) to (1955) as reported by ClinicalTrials.gov.
- 20 Aug 2008 New trial record.